South Korea · Delayed Price · Currency is KRW Aminologics Statistics
Total Valuation
Aminologics has a market cap or net worth of KRW 99.16 billion. The enterprise value is 62.76 billion.
| Market Cap | 99.16B |
| Enterprise Value | 62.76B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aminologics has 88.14 million shares outstanding. The number of shares has decreased by -2.42% in one year.
| Current Share Class | 88.14M |
| Shares Outstanding | 88.14M |
| Shares Change (YoY) | -2.42% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.96% |
| Owned by Institutions (%) | 0.17% |
| Float | 59.05M |
Valuation Ratios
The trailing PE ratio is 31.28.
| PE Ratio | 31.28 |
| Forward PE | n/a |
| PS Ratio | 3.79 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | 58.74 |
| P/OCF Ratio | 56.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.53, with an EV/FCF ratio of 37.18.
| EV / Earnings | 19.87 |
| EV / Sales | 2.40 |
| EV / EBITDA | 10.53 |
| EV / EBIT | 11.45 |
| EV / FCF | 37.18 |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.28 |
| Quick Ratio | 1.99 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 2.83 |
| Debt / FCF | 9.98 |
| Interest Coverage | 2.81 |
Financial Efficiency
Return on equity (ROE) is 5.58% and return on invested capital (ROIC) is 26.72%.
| Return on Equity (ROE) | 5.58% |
| Return on Assets (ROA) | 3.88% |
| Return on Invested Capital (ROIC) | 26.72% |
| Return on Capital Employed (ROCE) | 9.29% |
| Weighted Average Cost of Capital (WACC) | 7.44% |
| Revenue Per Employee | 638.00M |
| Profits Per Employee | 77.05M |
| Employee Count | 40 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.35 |
Taxes
In the past 12 months, Aminologics has paid 1.52 billion in taxes.
| Income Tax | 1.52B |
| Effective Tax Rate | 32.53% |
Stock Price Statistics
The stock price has increased by +15.02% in the last 52 weeks. The beta is 0.57, so Aminologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +15.02% |
| 50-Day Moving Average | 1,085.42 |
| 200-Day Moving Average | 1,259.65 |
| Relative Strength Index (RSI) | 47.89 |
| Average Volume (20 Days) | 162,619 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aminologics had revenue of KRW 26.16 billion and earned 3.16 billion in profits. Earnings per share was 35.97.
| Revenue | 26.16B |
| Gross Profit | 12.37B |
| Operating Income | 5.48B |
| Pretax Income | 4.68B |
| Net Income | 3.16B |
| EBITDA | 5.96B |
| EBIT | 5.48B |
| Earnings Per Share (EPS) | 35.97 |
Balance Sheet
The company has 53.24 billion in cash and 16.84 billion in debt, with a net cash position of 36.39 billion or 412.92 per share.
| Cash & Cash Equivalents | 53.24B |
| Total Debt | 16.84B |
| Net Cash | 36.39B |
| Net Cash Per Share | 412.92 |
| Equity (Book Value) | 58.43B |
| Book Value Per Share | 662.96 |
| Working Capital | 39.33B |
Cash Flow
In the last 12 months, operating cash flow was 1.76 billion and capital expenditures -75.70 million, giving a free cash flow of 1.69 billion.
| Operating Cash Flow | 1.76B |
| Capital Expenditures | -75.70M |
| Depreciation & Amortization | 479.51M |
| Net Borrowing | 19.71B |
| Free Cash Flow | 1.69B |
| FCF Per Share | 19.15 |
Margins
Gross margin is 47.29%, with operating and profit margins of 20.95% and 12.08%.
| Gross Margin | 47.29% |
| Operating Margin | 20.95% |
| Pretax Margin | 17.90% |
| Profit Margin | 12.08% |
| EBITDA Margin | 22.78% |
| EBIT Margin | 20.95% |
| FCF Margin | 6.45% |
Dividends & Yields
Aminologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.42% |
| Shareholder Yield | 2.42% |
| Earnings Yield | 3.19% |
| FCF Yield | 1.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 23, 2009. It was a forward split with a ratio of 5.
| Last Split Date | Oct 23, 2009 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Aminologics has an Altman Z-Score of 2 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2 |
| Piotroski F-Score | 5 |